Patent ID: 11939397
Assignee: NOVARTIS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 15:
16. The method of claim 12, wherein the at least one additional therapeutic agent is selected from:
i. a CTLA-4 inhibitor, optionally wherein the CTLA-4 inhibitor is selected from Ipilimumab or Tremelimumab;
ii. a TIM-3 inhibitor, optionally wherein the TIM-3 inhibitor is selected from MBG453, TSR-022, or LY3321367;
iii. a LAG-3 inhibitor, optionally wherein the LAG-3 inhibitor is selected from LAG525, BMS-986016, TSR-033, MK-4280 or REGN3767;
iv. a GITR agonist, optionally wherein the GITR agonist is selected from GWN323, BMS-986156, MK-4166, MK-1248, TRX518, INCAGN1876, AMG 228, or INBRX-110;
v. an anti-CD3 multispecific antibody molecule, optionally wherein the anti-CD3 multispecific antibody molecule is an anti-CD3×anti-CD123 bispecific antibody molecule (e.g., XENP14045), or an anti-CD3×anti-CD20 bispecific antibody molecule (e.g., XENP13676);
vi. a cytokine molecule, optionally wherein the cytokine molecule is IL-15 complexed with a soluble form of IL-15 receptor alpha (IL-15Ra);
vii. a macrophage colony-stimulating factor (M-CSF) inhibitor, optionally wherein the M-CSF inhibitor is MCS110;
viii. a CSF-1R inhibitor, optionally wherein the CSF-1R inhibitor is BLZ945;
ix. an inhibitor of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO);
x. a TGF-β inhibitor;
xi. an oncolytic virus; or,
xii. a chimeric antigen receptor (CAR) T-cell therapy.